Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Extragonadal germ cell tumor
Stage/Subtype:  recurrent extragonadal germ cell tumor
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-8 of 8 for your search:
Start Over
Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Other
Protocol IDs: 2013-062, NCI-2013-02001, P30CA022453, NCT01987596
High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 12 to 65
Sponsor: Other
Protocol IDs: 2008-0378, NCI-2011-01631, NCT00936936
PD 0332991 in Treating Patients With Refractory Solid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 03909, NCI-2009-01467, NCT01037790
Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IUCRO-0403, NCI-2013-00510, 1301010501, NCT01808534
Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HP-00040420, GCC 0805, NCT01110226
Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110148, 11-C-0148, NCT01341496
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: PM1183-A-007-13, NCT01831089
Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 29
Sponsor: Other
Protocol IDs: IRB00078790, NCT02390843
Start Over